Next Article in Journal
Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer
Next Article in Special Issue
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
Previous Article in Journal
Aptamer Cell-Based Selection: Overview and Advances
Previous Article in Special Issue
Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus
Open AccessReview

Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity

Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London W12 0NN, UK
*
Author to whom correspondence should be addressed.
Biomedicines 2017, 5(3), 50; https://doi.org/10.3390/biomedicines5030050
Received: 30 June 2017 / Revised: 4 August 2017 / Accepted: 10 August 2017 / Published: 22 August 2017
(This article belongs to the Special Issue Roles of NF-κB in Cancer and Their Therapeutic Approaches)
Transcription factors of the nuclear factor κB (NF-κB) family are central coordinating regulators of the host defence responses to stress, injury and infection. Aberrant NF-κB activation also contributes to the pathogenesis of some of the most common current threats to global human health, including chronic inflammatory diseases, autoimmune disorders, diabetes, vascular diseases and the majority of cancers. Accordingly, the NF-κB pathway is widely considered an attractive therapeutic target in a broad range of malignant and non-malignant diseases. Yet, despite the aggressive efforts by the pharmaceutical industry to develop a specific NF-κB inhibitor, none has been clinically approved, due to the dose-limiting toxicities associated with the global suppression of NF-κB. In this review, we summarise the main strategies historically adopted to therapeutically target the NF-κB pathway with an emphasis on oncology, and some of the emerging strategies and newer agents being developed to pharmacologically inhibit this pathway. View Full-Text
Keywords: nuclear factor κB; NF-κB inhibitors; cancer; IκB kinase; Gadd45β; ubiquitin nuclear factor κB; NF-κB inhibitors; cancer; IκB kinase; Gadd45β; ubiquitin
Show Figures

Graphical abstract

MDPI and ACS Style

Begalli, F.; Bennett, J.; Capece, D.; Verzella, D.; D’Andrea, D.; Tornatore, L.; Franzoso, G. Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines 2017, 5, 50. https://doi.org/10.3390/biomedicines5030050

AMA Style

Begalli F, Bennett J, Capece D, Verzella D, D’Andrea D, Tornatore L, Franzoso G. Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines. 2017; 5(3):50. https://doi.org/10.3390/biomedicines5030050

Chicago/Turabian Style

Begalli, Federica; Bennett, Jason; Capece, Daria; Verzella, Daniela; D’Andrea, Daniel; Tornatore, Laura; Franzoso, Guido. 2017. "Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity" Biomedicines 5, no. 3: 50. https://doi.org/10.3390/biomedicines5030050

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop